OncoSec Medical To Present at Bioelectrochemistry Gordon Research Conference on July 8 and July 10

SAN DIEGO-- OncoSec Medical Inc. (OTCQB: ONCS), a company developing its ImmunoPulse DNA-based intratumoral cancer immunotherapy, announces that Robert Pierce, M.D., Chief Medical Officer, and Richard Heller, Ph.D., Scientific Advisory Board member, will present at the Bioelectrochemistry Gordon Research Conference being held July 6-11, 2014 at the University of New England in Biddeford, ME.

Dr. Pierce will present a discussion titled “GET-IT! Intratumoral Electro-Gene Transfer of Immunomodulatory DNA in Oncology" on Tuesday, July 8 at 12:00 pm ET. The discussion will be a part of the track titled “Pore-Inducing Methods for Gene Transfer.”

Dr. Heller will present a discussion titled “New Developments in Gene Electro Transfer and Potential Clinical Translation” on Thursday, July 10 at 8:30 pm ET. The discussion will be a part of the track titled “Electroporation-Mediated Gene Delivery.”

About the Bioelectrochemistry Gordon Research Conference

The 2014 Gordon Research Conference will bring together leading researchers and clinicians to focus on molecular mechanisms related to the many aspects of bioelectrochemistry, and to discuss new and innovative studies that will expand our knowledge and appreciation of the field. The conference is unique in its design to bring together key field leaders to consider how these techniques can be developed further to yield novel clinical applications. While the meeting covers many divergent areas, great emphasis will be placed on stressing the connections between the planned sessions so that all participants are engaged to create a unified meeting. Attendees are encouraged to present posters that stimulate additional discussions, and the conference provides an excellent opportunity for junior researchers to present their work to leaders in the field within a uniquely constructive atmosphere. For more information, please visit the conference web site via the following link: http://www.grc.org

About OncoSec Medical Inc.

OncoSec Medical Inc. is a biopharmaceutical company developing its ImmunoPulse immunotherapy to treat solid tumors. OncoSec Medical's core technology leverages a proprietary electroporation platform to enhance the local delivery and uptake of DNA IL-12 and other DNA-based immune-modulating agents. Clinical studies of ImmunoPulse have demonstrated an acceptable safety profile and preliminary evidence of anti-tumor activity in the treatment of various skin cancers, as well as the potential to initiate a systemic immune response without the systemic toxicities associated with other treatments. OncoSec's clinical programs currently include three Phase 2 trials targeting metastatic melanoma, Merkel cell carcinoma and cutaneous T-cell lymphoma, conducted in collaboration with several prominent academic medical centers. As the company continues to evaluate ImmunoPulse in these indications, it is also investigating additional indications and combination therapeutic approaches. For more information, please visit www.oncosec.com.

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such “forward-looking statements.” Forward-looking statements are based on management’s current preliminary expectations and are subject to risks and uncertainties, which may cause our results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include our ability to raise additional funding, our ability to acquire, develop or commercialize new products, uncertainties inherent in pre-clinical studies and clinical trials, unexpected new data, safety and technical issues, competition, and market conditions. These and additional risks and uncertainties are more fully described in OncoSec Medical’s filings with the Securities and Exchange Commission. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. OncoSec Medical disclaims any obligation to update any forward-looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.

OncoSec Medical Inc.
Veronica Vallejo, CFO

Source: OncoSec Medical Inc.